1992
DOI: 10.1016/0014-2999(92)90508-2
|View full text |Cite
|
Sign up to set email alerts
|

Dose-dependent conditioned place preference produced by etonitazene and morphine

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
6
0

Year Published

1993
1993
2012
2012

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 30 publications
(6 citation statements)
references
References 34 publications
0
6
0
Order By: Relevance
“…Because only one dose of each drug was examined, it cannot be determined from the place-conditioning data alone whether these differences in sensitivity reflect potency or efficacy differences between the two groups. However, it is unlikely that the effects observed at the selected doses were atypical, as both mu-opiods (Sala et al 1992;Steinpreis et al 1996;Zarrindast et al 2004) and kappa-opiods (Shippenberg and Herz 1988;Suzuki et al 1992;Funada et al 1993) produce linear effects in this procedure.…”
Section: Discussionmentioning
confidence: 95%
“…Because only one dose of each drug was examined, it cannot be determined from the place-conditioning data alone whether these differences in sensitivity reflect potency or efficacy differences between the two groups. However, it is unlikely that the effects observed at the selected doses were atypical, as both mu-opiods (Sala et al 1992;Steinpreis et al 1996;Zarrindast et al 2004) and kappa-opiods (Shippenberg and Herz 1988;Suzuki et al 1992;Funada et al 1993) produce linear effects in this procedure.…”
Section: Discussionmentioning
confidence: 95%
“…In vivo , morphine does not promote significant µ receptor down‐regulation even under conditions that induce profound cellular tolerance (Stafford et al ., 2001; Gomes et al ., 2002; Patel et al ., 2002; Pawar et al ., 2007; Grecksch et al ., 2011). When administered chronically at equieffective analgesic doses, etonitazene or methadone, which are potent inducers of µ receptor internalization, produce less tolerance than morphine (Sala et al ., 1992; Elmer et al ., 1993; Gerak and France, 1996; 1997; Walker and Young, 2001; Grecksch et al ., 2006; Hull et al ., 2009). We found that GRK5 selectively contributes to morphine‐induced Ser 375 phosphorylation in mouse brain.…”
Section: Discussionmentioning
confidence: 99%
“…However, morphine is a particularly poor inducer of µ‐opioid receptor endocytosis, but a potent inducer of cellular tolerance (Arden et al ., 1995; Keith et al ., 1996; Alvarez et al ., 2001; Schulz et al ., 2004; Gintzler and Chakrabarti, 2006; Johnson et al ., 2006; McPherson et al ., 2010). Conversely, full agonists such as fentanyl or etonitazene elicit robust µ receptor internalization but less tolerance (Elmer et al ., 1993; Gerak and France, 1996; 1997; Sala et al ., 1992; Walker and Young, 2001; Grecksch et al ., 2006; 2011; Hull et al ., 2009). We have recently generated phosphosite‐specific antibodies for the carboxyl‐terminal residues threonine 370 (Thr 370 ) and serine 375 (Ser 375 ), which enabled us to selectively detect either the Thr 370 ‐phosphorylated or the Ser 375 ‐phosphorylated form of the µ receptor.…”
Section: Introductionmentioning
confidence: 99%
“…First, we attempted to bypass the problem by using an opioid with a very high potency. Etonitazene has been estimated to be 2000 times more potent than morphine in eliciting analgesia (Rosow et al 1980), and it produces dose-dependent place preference at doses as low as 2.5-15 gg/kg IP (Sala et al 1992). Therefore, pharmacologically active amounts can be obtained by drinking only moderate volumes of weak solutions with very little bitter taste.…”
Section: Discussionmentioning
confidence: 97%